Patrys Ltd PATLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,423.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.patrys.com
Valuation
|
Metric
|
PATLF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.39 |
Price/Sales | 2,423.78 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PATLF
|
|---|---|
Quick Ratio | 8.95 |
Current Ratio | 8.95 |
Interest Coverage | — |
Quick Ratio
PATLF
Profitability
|
Metric
|
PATLF
|
|---|---|
Return on Assets (Normalized) | −56.65% |
Return on Equity (Normalized) | −64.43% |
Return on Invested Capital (Normalized) | −66.21% |
Return on Assets
PATLF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qyzjttdd | Tvsrb | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vqxcjcck | Kbctpl | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lwtftck | Jmxlzg | $98.1 Bil | |
MRNA
| Moderna Inc | Zjlyfgy | Gfgjf | $39.1 Bil | |
ARGX
| argenx SE ADR | Lsgrhjd | Psglz | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Nhzpzqp | Bzmq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Szblvmc | Pmgycl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zzpqckxm | Vrvkypz | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jykdzwxcy | Rdjmgf | $12.5 Bil | |
INCY
| Incyte Corp | Kvtbytz | Cyqylp | $11.9 Bil |